GLOBAL MICAFUNGIN SODIUM FOR INJECTION MARKET 2019 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2024

Delivery of the Report will take 2-3 working days once order is placed.

Synopsis

Micafungin (trade name Mycamine) is an echinocandin antifungal drug used to treat and prevent invasive fungal infections including candidemia, abscesses and esophageal candidiasis. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.

Scope of the Report:
In 2013, Japan was the largest consumption place, with a consumption market share nearly 35.40%. In 2017, North America is the largest consumption place with the consumption market share of 28.98%.
Astellas is the leader of the industry, and it holds key technologies and patents, with high-end customers; has been formed in the monopoly position in the industry.
The worldwide market for Micafungin Sodium for Injection is expected to grow at a CAGR of roughly -4.6% over the next five years, will reach 290 million US$ in 2024, from 380 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Micafungin Sodium for Injection in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
- Astellas

Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
- 50 mg Single-use Vial
- 100 mg Single-use Vial

Market Segment by Applications, can be divided into
- Candidemia
- Respiratory Mycosis
- Gastrointestinal Mycosis

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Micafungin Sodium for Injection product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Micafungin Sodium for Injection, with price, sales, revenue and global market share of Micafungin Sodium for Injection in 2017 and 2018.
Chapter 3, the Micafungin Sodium for Injection competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Micafungin Sodium for Injection breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Micafungin Sodium for Injection market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Micafungin Sodium for Injection sales channel, distributors, customers, research findings and conclusion, appendix and data source.